Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Shares of Merck & Co. Inc. MRK inched 0.44% higher to $101.17 Thursday, on what proved to be an all-around mixed trading ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

With a market cap of $258 billion ... related charge impacting operating margins have further pressured Merck's stock performance. Moreover, despite reporting better-than-expected Q3 adjusted ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Shares of Merck & Co. Inc. MRK slipped 0.22% to $101.65 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.23% to 5,782 ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the ...

When a biopharmaceutical company brings a drug to market, they have patent protection ... 7.3% for the week ending November 1. By contrast, MRK stock is down 6.15% this year, with a drop of ...

Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple common share classes, market capitalization includes both classes.

The point is that Merck spent money developing and launching the Keytruda molecule once and, since then, has been ...

Sotatercept is the first activin signaling inhibitor therapy for PAH in Canada, a new class of therapy that works by improving the balance between pro-proliferative and anti-proliferative signaling to ...